Apogee Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Apogee Therapeutics's estimated annual revenue is currently $68.8M per year.
- Apogee Therapeutics's estimated revenue per employee is $264,573
Employee Data
- Apogee Therapeutics has 260 Employees.
- Apogee Therapeutics grew their employee count by 98% last year.
Apogee Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO at Apogee Therapeutics | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Commercial Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | SVP Tax | Reveal Email/Phone |
8 | VP, Clinical Pharmacology | Reveal Email/Phone |
9 | SVP, Research & Translational Medicine | Reveal Email/Phone |
10 | SVP, Commercial Strategy & Operations | Reveal Email/Phone |
Apogee Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Apogee Therapeutics?
Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders.
keywords:N/AN/A
Total Funding
260
Number of Employees
$68.8M
Revenue (est)
98%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $36.3M | 260 | -2% | $56.5M |
#2 | $39.1M | 260 | -4% | $183.2M |
#3 | $39.1M | 260 | -4% | $298.8M |
#4 | $41.5M | 260 | 67% | N/A |
#5 | $37.2M | 260 | -9% | $257M |